165 related articles for article (PubMed ID: 30657070)
1. Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion.
de Carvalho JF; Dos Santos MNP; de Oliveira JMV; Lanty Silva ANS; de Araujo RPC; Cardozo JB
Adv Rheumatol; 2018 Aug; 58(1):22. PubMed ID: 30657070
[TBL] [Abstract][Full Text] [Related]
2. Premedication prevents infusion reactions and improves retention rate during infliximab treatment.
Bartoli F; Bruni C; Cometi L; Blagojevic J; Fiori G; Tofani L; Galluccio F; Furst DE; Matucci Cerinic M
Clin Rheumatol; 2016 Nov; 35(11):2841-2845. PubMed ID: 27436188
[TBL] [Abstract][Full Text] [Related]
3. Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
Alves de Oliveira Junior H; Pereira da Veiga T; Acurcio FA; Almeida AM; Ribeiro Dos Santos JB; da Silva MRR; Kakehasi AM; Cherchiglia ML
Hosp Pract (1995); 2020 Oct; 48(4):213-222. PubMed ID: 32567403
[TBL] [Abstract][Full Text] [Related]
4. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
[TBL] [Abstract][Full Text] [Related]
5. Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry.
Choquette D; Faraawi R; Chow A; Rodrigues J; Bensen WJ; Nantel F
J Rheumatol; 2015 Jul; 42(7):1105-11. PubMed ID: 26077415
[TBL] [Abstract][Full Text] [Related]
6. Administration of infliximab in general practitioners' offices is safe.
Stuby U; Biesenbach G; Pieringer H
Clin Rheumatol; 2007 Nov; 26(11):1863-6. PubMed ID: 17322962
[TBL] [Abstract][Full Text] [Related]
7. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions.
Inciarte-Mundo J; Hernández MV; Rosario V; Ruiz-Esquide V; Cabrera-Villalba S; Ramírez J; Cañete JD; Sanmartí R
Reumatol Clin; 2014; 10(1):10-6. PubMed ID: 23876791
[TBL] [Abstract][Full Text] [Related]
8. Dose reduction of biologic therapy in inflammatory arthritis: A qualitative study of patients' perceptions and needs.
Hewlett S; Haig-Ferguson A; Rose-Parfitt E; Halls S; Freke S; Creamer P
Musculoskeletal Care; 2019 Mar; 17(1):63-71. PubMed ID: 30398699
[TBL] [Abstract][Full Text] [Related]
9. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
10. A real-world, multi-site, observational study of infusion time and treatment satisfaction with rheumatoid arthritis patients treated with intravenous golimumab or infliximab.
Daniel SR; McDermott JD; Le C; Pierce CA; Ziskind MA; Ellis LA
J Med Econ; 2018 Jul; 21(7):724-731. PubMed ID: 29718743
[TBL] [Abstract][Full Text] [Related]
11. Infliximab treatment for rheumatic disease: clinical and radiological efficacy.
St Clair EW
Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii67-9. PubMed ID: 12379627
[TBL] [Abstract][Full Text] [Related]
12. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.
Nikiphorou E; Kautiainen H; Hannonen P; Asikainen J; Kokko A; Rannio T; Sokka T
Expert Opin Biol Ther; 2015; 15(12):1677-83. PubMed ID: 26549204
[TBL] [Abstract][Full Text] [Related]
14. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
[TBL] [Abstract][Full Text] [Related]
15. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
16. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
[TBL] [Abstract][Full Text] [Related]
17. Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients.
Antonio JR; Sanmiguel J; Cagnon GV; Augusto MS; Godoy MF; Pozetti EM
An Bras Dermatol; 2016; 91(3):306-10. PubMed ID: 27438197
[TBL] [Abstract][Full Text] [Related]
18. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis.
Codreanu C; Šírová K; Jarošová K; Batalov A
Curr Med Res Opin; 2018 Oct; 34(10):1763-1769. PubMed ID: 29439591
[TBL] [Abstract][Full Text] [Related]
19. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
[TBL] [Abstract][Full Text] [Related]
20. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.
Huscher D; Merkesdal S; Thiele K; Zeidler H; Schneider M; Zink A;
Ann Rheum Dis; 2006 Sep; 65(9):1175-83. PubMed ID: 16540552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
